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A B S T R A C T   
Background: Several rare copy number variants have been identified to confer risk for neurodevelopmental 
disorders (NDD-CNVs), and increasingly NDD-CNVs are being identified in patients. There is a clinical need to 
understand the phenotypes of NDD-CNVs. However due to rarity of NDD-CNVs in the population, within indi-
vidual countries there is a limited number of NDD-CNV carriers who can participate in research. The pan- 
european MINDDS (Maximizing Impact of Research in Neurodevelopmental Disorders) consortium was estab-
lished in part to address this issue. 
Methodology: A survey was developed to scope out the current landscape of NDD-CNV research across member 
countries of the MINDDS consortium, and to identify clinical cohorts with potential for future research. 
Results: 36 centres from across 16 countries completed the survey. We provide a list of centres who can be 
contacted for future collaborations. 3844 NDD-CNV carriers were identified across clinical and research centres 
spanning a range of medical specialties, including psychiatry, paediatrics, medical genetics. A broad range of 
phenotypic data was available; including medical history, developmental history, family history and anthro-
pometric data. In 12/16 countries, over 75% of NDD-CNV carriers could be recontacted for future studies. 
Conclusion: This survey has highlighted the potential within Europe for large multi-centre studies of NDD-CNV 
carriers, to improve knowledge of the complex relationship between NDD-CNV and clinical phenotype. The 
MINNDS consortium is in a position to facilitate collaboration, data-sharing and knowledge exchange on NDD- 
CNV phenotypes across Europe.   
1. Introduction 
Advances in genetic technologies in the past decade have led to the 
discovery of new pathogenic genetic variants which are making signif-
icant contributions to the way we understand neuropsychiatric disor-
ders. Discovery of copy number variants (CNVs) in the human genome 
allows us to study patients with a shared genetic aetiology, thus 
employing a “genotype-first approach” rather than a classical “pheno-
type-first approach” as has been traditionally done in psychiatry (Lord 
and Veenstra-VanderWeele, 2016). CNVs include microdeletions and 
microduplications of DNA of multiple sizes (Grayton et al., 2012). These 
structural chromosomal modifications can be limited to a single gene or 
include many genes and can occur either de novo or be inherited. CNVs 
significantly contribute to inter-individual variation and while some are 
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benign, others predispose to diseases (Bijlsma et al., 2009; Männik et al., 
2015; Sebat et al., 2004; Watson et al., 2014). Some pathogenic CNVs 
tend to be highly variable in penetrance and expressivity. A number of 
rare CNVs have been associated with increased risk for neuro-
developmental disorders (NDD-CNVs). The term NDD encompasses a 
range of disorders including autism spectrum disorder (ASD), develop-
mental disorder/intellectual disability (DD/ID), attention deficit/-
hyperactivity disorder (ADHD), and schizophrenia (SCZ). NDDs occur in 
about 4% of the population and tend to impact individuals throughout 
their life-span (Mitchell, 2011). Studying CNVs offers unique opportu-
nities to elucidate the genetic basis of NDDs (Doherty and Owen, 2014; 
Gudmundsson et al., 2019; Kirov et al., 2014; Marshall et al., 2017; 
Owen, 2014; Sanders et al., 2015). 
An increasing number of recent studies indicate that NDDs share 
genetic mechanisms, and suggest that NDD-CNVs have a pleiotropic 
effect on clinical phenotypes and potentially impact convergent under-
lying brain pathways (de la Torre-Ubieta et al., 2016; Gudmundsson 
et al., 2019). 22q11.2 deletion syndrome (22q11.2DS) is an example of a 
NDD-CNV with pleiotropic effects across the lifespan. Individuals with 
22q11.2DS may present with congenital abnormalities, immunological 
dysfunction, epilepsy and seizures, intellectual disability, development 
coordination disorder, ADHD, ASD, anxiety disorder and sleep distur-
bances in childhood as well as high risk of schizophrenia and Parkin-
son’s disease in adulthood (Bassett et al., 2005; Bassett et al., 1998; Boot 
et al., 2018; Cunningham et al., 2018; Eaton et al., 2019; Jonas et al., 
2014; McDonald-McGinn et al., 2015; Moulding et al., 2020; Murphy 
et al., 1999; Niarchou et al., 2014; Schneider et al., 2014), and there is a 
high degree of co-occurrence of neurodevelopmental and psychiatric 
symptoms, neurological traits and sleep disturbances in 22q11.2DS 
(Cunningham et al., 2018; Cunningham et al., 2020; Eaton et al., 2019; 
McDonald-McGinn et al., 2015; Moulding et al., 2020; Mullen et al., 
2013; Niarchou et al., 2014). Multimorbidity carries a great burden both 
for the affected individual, their families and wider society, and current 
clinical care focuses mainly on treatment of presenting symptoms, rather 
than targeting the underlying neuropathology. Understanding the 
pathophysiological mechanisms of NDD-CNVs is crucial for the devel-
opment of improved and tailored treatments. Furthermore, better un-
derstanding of the relationship between behavioral phenotype and 
underlying genetic factors will inform optimal genetic counselling and 
clinical care. 
Progress with research into NDD-CNVs is however hampered by the 
fact that patients with these variants are rare posing challenges for re-
searchers to bring together samples that are sufficiently powered to 
address important research questions. The pleiotropic effects of NDD- 
CNVs indicate that wide-ranging assessments should be conducted to 
capture the complex phenotypic presentation of these patients (Chawner 
et al., 2019), which should ideally go beyond clinical records to include 
other informative measures such as neurocognitive skills (Chawner 
et al., 2017; D’Angelo et al., 2016; Vorstman et al., 2015), motor func-
tion (Cunningham et al., 2019, 2020), physical health problems such as 
seizures (Eaton et al., 2019), sleep disturbances (Moulding et al., 2020) 
and brain imaging (Maillard et al., 2015; Sun et al., 2020; van der Meer 
et al., 2020). It is therefore important for clinicians and researchers to 
join efforts to gather large datasets in order to draw valid conclusions. 
The MINDDS (Maximizing Impact of Research in Neurodevelopmental 
Disorders) consortium was established in part to address this issue. 
The MINDDS consortium is a 4 year EU-funded COST action pan- 
European collaborative network established in 2017 (CA16210), 
https://mindds.eu/. This consortium aims to maximize research impact 
of the study of rare individuals with NDD-CNVs to gain better under-
standing, and contribute towards improved diagnosis and new treat-
ments. MINDDS has five working groups (WGs) that focus on: (1) patient 
cohort framework; (2) clinical phenotyping, (3) emerging technologies, 
(4) databases and informatics; (5) and integration and convergence. It 
has brought together clinicians, researchers, and patient organizations 
from 30 EU countries and COST member/co-operating states to design 
and develop an approach for transnational patient recruitment with 
standardized protocols, incorporating regulatory, legal and ethical 
requirements. 
The MINDDS Consortium includes 2 executive full members and 2 
substitute members for each of the 30 countries involved in the Action: 
Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, 
Israel, Italy, Latvia, Malta, Montenegro, The Netherlands, Norway, 
Poland, Portugal, Romania, Serbia, Spain, Sweden, Switzerland, Turkey, 
United Kingdom and the Republic of North Macedonia. 
WG2 of the MINDDS action focuses on deep clinical phenotyping and 
harmonizing standardized assessment tools for NDD-CNV research. As 
one of its goals, WG2 aims to review current methodologies and survey 
common research practices across COST participating countries and 
international partners. As part of this effort, WG2 aims to gain a clearer 
picture of the research into NDD-CNVs conducted in COST member and 
co-operating states; in order to provide a basis for large-scale multi- 
centre research collaborations. This is important as currently most 
published NDD-CNV research is still based on one-site studies and 
therefore relatively in small scale. Large international networks such as 
MINDDS are needed to be able to fully capture the variable complex and 
overlapping phenotypes of NDD-CNVs. 
2. Methods 
A survey was developed by MINDDS WG2 with the aim of gaining a 
clearer picture of the NDD-CNV research, more specifically about NDD- 
CNV projects that respondents may have conducted or have been 
involved with. Furthermore, respondents were asked about clinical co-
horts they had access to and which offered a potential for new research. 
MINDDS focused on NDD-CNVs based on their prevalence as well as 
robustness of evidence of association with NDDs (Brunetti-Pierri et al., 
2008; Dolcetti et al., 2013; Hoeffding et al., 2017; Kushima et al., 2017; 
McDonald-McGinn et al., 2015; Niarchou et al., 2019; Ye et al., 2012). 
These included deletions and duplications at the following loci: 1q21.1, 
2p16.3 (NRXN1), 3q29, 7q11.23, 9q34.3 (Kleefstra Syndrome), 
15q11.2, 15q11-13, 15q13.3, 16p11.2 (breakpoint 4–5), 16p11.2 distal, 
16p13.11, 17q12, 22q11.2 (Velo-Cardio-Facial Syndrome), 22q13.3 
(Phelan-McDermid Syndrome). The survey was designed to take 30 min 
to complete. 
The survey was developed by WG2 of the MINDDS consortium via 
several stages of stakeholder engagement in the MINDDs consortium 
(Fig. 1). Initially, WG2 held a meeting of the MINDDS consortium in 
which a scoping exercise was undertaken whereby clinical and research 
stakeholders from member countries provided open-ended information 
about NDD-CNV research and clinical cohorts within their country. This 
scoping exercise identified the key questions to take forward by WG2 to 
develop into a survey. The wording of the survey questions was 
reviewed by WG2 clinical and researcher members to ensure the survey 
was accessible and was interpreted consistently across countries. WG2 
members then piloted the survey with clinical and research colleagues to 
demonstrate feasibility. The survey was then finalized at a WG2 
meeting. Through this process it became clear that the survey had to be 
appropriate both for research studies and clinical cohorts where there 
was potential for research. 
The survey asked respondents for contact details for their research 
and/or clinical centre and for the frequency of NDD-CNV carriers, by 
variant, whereby (a) research data was available (b) clinically identified 
individuals where there was potential for research. Further questions 
were asked regarding the range of phenotypic measures collected, the 
extent to which individuals could be re-contacted, the age category of 
individuals, the referral pathway by which patients were ascertained 
and the method of genetic testing used (See Appendix 1). 
The representatives of each country identified locally the research 
and clinical centres the survey should be distribute. We did not aim to 
capture all research and clinical centres within each country, rather the 
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aim was to capture data from centres that indicated interest in future 
research and collaboration via the MINDDS consortium. 
The survey was launched in May 2019 and was distributed to the 
MINDDS consortium executive members from each country. Data 
collection ended in December 2019. Following guidance from Cardiff 
University ethics committee, the survey was developed in agreement 
with GDPR legislation (further details in Appendix 1). 
3. Results 
38 countries are eligible to be part of COST actions including 
MINDDS, and at the time of the survey 30 countries were engaged in the 
MINDDS consortium. Of these 30 countries, a total of 23 countries (77% 
of MINDDS countries) responded to the survey. Out of the 23, 16 were 
able to provide full responses on the majority of questions, which was 
the inclusion criteria for the study. Barriers for the 7 countries where it 
was not possible to complete the survey in full, included lack of access to 
centralized healthcare data on genetic testing, and/or lack of routine 
genetic testing in the country. 2 of these 7 countries (Bosnia & Herze-
govina and North Macedonia) did provide preliminary information, and 
indicated potential for research in their countries. Within the 16 coun-
tries that were able to provide full information, we received 9 responses 
from Turkey, 4 from Croatia, 4 from UK, 3 from Netherlands, 3 from 
Poland, 2 from Portugal, 2 from Romania, and 1 each from Belgium, 
Bulgaria, Ireland, Israel, Denmark, Montenegro, Norway, Serbia, and 
Switzerland (Fig. 1). This resulted in responses from 36 centres across 
MINDDS countries (see Appendix 2 for details and contact information). 
Responses were received from individuals from a range of professional 
backgrounds (Fig. 2). Fig. 3 shows that there is an overlap in the spe-
cialties studying/providing care for patients with NDD-CNVs across 
countries that completed our survey. Responses came from medical 
geneticists in 10 countries, academic and clinical researchers in 10 
countries, psychiatrists/psychologists in 5 countries, and pediatricians 
in 3 countries. 
3.1. Number of CNV carriers 
13 countries (81%) reported on-going studies into NDD-CNVs. Most 
are involved in 22q11.2DS (9/13), with other NDD-CNVs studied 
including 22q11 duplication (3/13), 16p11.2 deletion and duplication 
(2/13), NRXN1 deletion (1/13), 1q21.1 deletion (1/13), and Kleefstra 
syndrome (1/13). Some of the research groups focused on investigating 
NDD-CNVs which can be found in ASD (1/13) or during postnatal di-
agnostics (1/13). Three countries did not report current research 
regarding NDD-CNVs; patients in these countries are diagnosed for 
clinical purposes with the potential for future research and collabora-
tion. In addition, although not all centres within countries are currently 
involved in research, some have the potential to do so. Table 1 provides 
a summary of the approximate numbers of individuals with NDD-CNV 
available for research based on our survey. Across MINDDS countries, 
3844 NDD-CNV carriers were identified. 
Across Europe, testing for NDD-CNVs takes place across the lifespan 
spanning from prenatal testing (50%, 8/16) to childhood (94%, 15/16), 
adolescence (69%, 11/16) and adulthood (75%, 12/16). Initial referral 
reasons for CNV testing varied and included neurodevelopmental delay 
in 14 countries (87%), neuropsychiatric issues in 11 countries (69%), 
Fig. 1. Development of the survey.  
Fig. 2. MINDDS countries that took part in survey.  
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congenital malformations in 11 countries (69%), and potential familial 
inheritance in 8 countries (50%). 
3.2. Summary of current data available from sites 
A broad range of methods have been used for NDD-CNV screening 
across Europe. Most of the countries (88%, 14/16) reported use of 
microarray (CGH), followed by the FISH method (63%, 10/16), while 
lower frequencies were observed for whole genome sequencing (38%, 6/ 
16) and exome sequencing (38%, 6/16). 
MINDDS members were asked to report the range of phenotypic data 
available. All countries reported availability of medical history, devel-
opmental history, family history and anthropometric data. The majority 
(94%, 15/16) also reported data on educational history, neuropsycho-
logical evaluations including IQ testing, as well as treatment and 
intervention history. 63% (10/16) reported availability of psychiatric 
data. Regarding biological data, all countries had DNA samples available 
within their cohorts; whilst only 13% (2/16) had original blood samples 
available, 13% (2/16) had RNA samples available, 6% (1/16) had iPS 
cells, 6% (1/16) EBV cell lines, 6% (1/16) amniotic cells, and 6% (1/16) 
fetal material. Regarding neurophysiological data, 75% (12/16) of the 
countries reported MRI (structural and/or functional), 69% (11/16) 
EEG, 6% (1/16) MEG, 56% (9/16) audiological testing, 31% (5/16) eye- 
tracking, and 12.5% (2/16) wearables data available. 
One of the major challenges in future studies and collaborations is 
the possibility to re-contact the patients with NDD-CNVs. 4 countries 
reported that all participants could be re-contacted, 8 countries reported 
that 75% of participants could be re-contacted, 3 countries reported that 
50% could be re-contacted, and 1 country reported that 25% could be re- 
contacted. 
4. Discussion 
We developed a survey which aimed to capture the landscape of 
clinical and research cohorts of patients with NDD-CNVs across Europe, 
to inform the potential of conducting large scale research studies. We did 
not set out to capture every diagnosed NDD-CNV carrier in Europe, 
rather this survey aimed to capture information from research and 
clinical centres where there would be potential and enthusiasm for 
contributing to future collaborative research on NDD-CNV carriers. 
Through the MINNDS consortium, 36 clinical and research centres 
across 16 countries completed the survey. Appendix 2 provides a useful 
resource to the European research community in developing new in-
ternational collaborations focused on NDD-CNVs. The majority of re-
spondents were working in the field of medical/clinical genetics, 
psychology/psychiatry and pediatrics, mostly in a position as both 
clinician and researcher. 3844 NDD-CNV carriers were identified across 
Europe, and centres provided information indicating availability of a 
range of genetic and phenotypic data, as well as the extent to which 
participants could be re-contacted and data shared. This survey repre-
sents a first step to a pan-European approach to understanding the 
clinical phenotype of NDD-CNV carriers. 
Results of the survey provided a broad perspective of the current 
situation regarding clinical and research practice within MINDDS con-
sortium. Firstly, we queried the professional backgrounds of the re-
spondents. We found that the majority were medical geneticists, who 
tended to combine clinical (psychiatrists, psychologists, pediatricians) 
and research duties. In a few countries we received reports from only 
academic researchers, and in one from clinician only. This could indi-
cate a need for greater awareness and education of clinicians regarding 
contribution of CNVs in NDDs. For example, few recent papers 
addressed this issue with topics related to increasing genetic knowledge 
in psychiatrists (Grimm et al., 2020; Nurnberger et al., 2018), and 
particularly regarding CNVs (Sullivan and Owen, 2020). Increased 
awareness of the contribution of rare genetic conditions to clinical 
diagnosis in fields such as psychiatry/psychology, pediatrics, cardiol-
ogy, neurology and occupational therapy, should improve building a 
multidisciplinary clinical network in providing a diagnosis on time, as 
well as specific care and treatment for patients with NDD-CNVs. 
Furthermore, most of the countries (14/16) reported that the main 
referral reason for NDD-CNV testing was neurodevelopmental delay. 
Neuropsychiatric symptoms and congenital malformations were reasons 
Fig. 3. Overlap in professional background of respondents; numbers refer 
to countries. 
Table 1 
Approximate numbers of NDD-CNV carriers reported among professionals 
within MINDDS countries.  
CNV Clinicians Researchers Both Total 
1q21.1del 14 52 37 103 
1q21.1dup 4 57 18 79 
NRXN1del 7 105 59 171 
NRXN1dup 0 2 5 7 
3q29del 2 10 11 23 
3q29dup 2 2 7 11 
7q11.23del 13 6 179 198 
7q11.23dup 1 5 17 23 
9q34.3del 5 29 28 62 
9q34.3dup 0 4 2 6 
15q11.2del 16 106 148 270 
15q11.2dup 14 32 34 80 
15q11-13del 10 7 284 301 
15q11-13dup 1 6 32 39 
15q11.3del 7 44 61 112 
15q11.3dup 9 94 17 120 
16p11.2del 8 115 191 314 
16p11.2dup 1 56 171 228 
16p11.2distaldel 2 5 17 24 
16p11.2distaldup 1 2 18 21 
16p13.11del 4 9 38 51 
16p13.11dup 9 14 28 51 
17q12del 0 2 17 19 
17q12dup 5 6 27 38 
22q11.2del 58 354 788 1200 
22q11.2dup 6 57 116 179 
22q13.3del 7 3 98 108 
22q13.3dup 1 1 4 6 
TOTAL 207 1185 2452 3844  
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for testing in 11 countries, while family history was reported as indi-
cation for testing in 8 of the countries. These results are similar to the 
findings for the most common indications for testing for 22q11.2 dele-
tion syndrome (Swillen and McDonald-McGinn, 2015). Referral reasons 
varied across Europe, possibly reflecting differing clinical and research 
practices. This points to a need for the development of European clinical 
guidelines to underpin referral procedures and to increase awareness of 
these conditions in NDDs. 
In addition, children were the most tested group in all countries, 
while adolescents and adults were tested less frequently, potentially 
reflecting current bias in referral for genetic testing. It may also reflect 
the fact that the largest group of responders to our study were pedia-
tricians, who may have greater awareness of NDD-CNVs. Nonetheless, 
our findings are in accordance with phenotypic studies which indicate 
that diagnosis of clinical symptoms occurs most frequently in the post-
natal or early childhood period (Swillen and McDonald-McGinn, 2015). 
Finally, the results of our survey provide a perspective of ongoing 
NDD-CNV research, availability of biological and phenotype data, as 
well as numbers of NDD-CNV carriers in countries which are less 
research intensive or have conducted no research in this field. One of the 
aims of the overall COST initiative is to stimulate research in countries 
that have been historically less research intensive. There is great po-
tential to achieve this in MINDDS as many NDD-CNV clinical cohorts 
which offer potential for research in currently less research-intensive 
countries are accessible via the MINDDS consortium. In fact, approxi-
mate numbers of NDD-CNV carriers presented in Table 1 revealed great 
potential for extension of collaborations in on-going research fields as 
well as for new collaborations. According to the literature, there are 
currently two international consortiums focusing on ND-CNV, related to 
22q11.2 deletion syndrome and 16p11.2 deletion and duplication 
(D’Angelo et al., 2016; Gur et al., 2017; Schneider et al., 2014). Numbers 
of European carriers identified in our survey are larger than cohorts of 
European carriers in existing consortia; 16p11.2 duplication, MINDDS 
total = 228 vs European carriers in existing consortia total = 127; 
16p11.2 deletion, MINDDS total = 314 vs European carriers in existing 
consortia total = 222; 22q11.2 deletion, MINDDS total = 1200 vs Eu-
ropean carriers in existing consortia total = 976 (D’Angelo et al., 2016; 
Gur et al., 2017; Schneider et al., 2014). Our survey indicates there is 
huge potential for large-scale study of NDD-CNV carriers from Europe, 
as some, but not all are involved in current consortia, indicating po-
tential for collaborations that increases diversity and sample size of 
cohorts in Europe. Regarding other NDD-CNVs, numbers are higher 
compared to individual study cohorts (Al Shehhi et al., 2019; Bernier 
et al., 2016; Chawner et al., 2019). There is a broad range of phenotypic 
data that is collected across the countries including clinical, neuro-
imaging, and electrophysiological data. All countries reported to have 
medical history, developmental history, family history and anthropo-
metric data, majority have cognitive data, while psychiatric data are less 
present. One of the reasons could be lack of knowledge and involvement 
of psychiatrists in NDD-CNV research, which again highlights a need for 
further genetic education. 
As far as we know, this survey is the first of its kind to capture the 
potential for NDD-CNV research across Europe. However, the survey 
findings should be considered in light of some limitations. Specifically, 
some of the sites that responded focused on the study or treatment of a 
limited range of CNVs. This may be attributable to a specific research 
focus or the clinic’s scope for diagnosing rare genomic disorders (such as 
22q11.2 deletion and 7q11.23 deletion), leading to ascertainment bias. 
In addition, it should be noted that our survey focused on well- 
characterized pathogenic CNVs in NDDs, however, although there is 
increasing research evidence for the role of non-coding CNVs in NDDs, 
these, were not covered by this survey. However, the MINDDS con-
sortium provides a framework for collaboration that can be applied to 
newly discovered variants in the future. Furthermore, not every country 
in the MINDDS network completed the survey, and in our results, we 
highlighted some of the barriers (in some countries) in completing the 
survey, often due to lack of access to centralized records. Lack of re-
sponses from some countries indicate that not all countries may have the 
resources or infrastructures to currently contribute to collaborative 
studies or would require additional resources to participate in interna-
tional research networks. However, it is encouraging that the survey was 
completed by many countries classified by COST as Inclusiveness Target 
Countries which are currently not research-intensive. This demonstrates 
great potential for future European research networks that are more 
inclusive of a wider range of countries, and therefore more likely to 
capture how the phenotype of NDD-CNVs is expressed across a range of 
cultural, ethnic and socioeconomic settings. Moreover, our study high-
lights interest for building larger multi-centre studies on NDD-CNVs 
including countries which are traditionally less research-intensive. In-
ternational consortia have the potential to provide platforms for facili-
tating the research potential of countries that have been traditionally 
less research-intensive, leading to large highly-powered research pro-
grammes that have greater representation of the diversity of patients as 
well as the talent of researchers that exists across Europe. Networks like 
MINDDS represent a framework for establishing such a converging 
research platform which will (a) contribute to and increase/improve our 
knowledge and understanding of the link between CNV and NDD phe-
notypes; (b) improve care and quality of life for CNV carriers and their 
families. 
An important step in delivering a pan-European study will be the 
harmonization of previously collected data and standardizing pheno-
typic protocols for future data collection. This will require the consid-
eration of several issues including (a) developing a protocol that is 
feasible across a range of clinical and research centres with varying 
constraints on resources and contact time with patients, (b) creating 
protocols that can be delivered in a range of languages and are appro-
priate across the cultural diversity in Europe, and (c) developing data-
bases and data collection procedures suitable for large scale multi-site 
studies involving potentially sensitive data. Within MINDDS, a training 
school was conducted to start to discuss and address some of these issues 
(https://mindds.eu/activities/training-schools/skopje/). As mentioned 
before, there have been some initial collaborative efforts for the 22q11.2 
Deletion and 16p11.2 Deletion and Duplication NDD-CNVs, but argu-
ably these collaborations have not involved a diverse range of European 
countries (D’Angelo et al., 2016; Gur et al., 2017), and have been limited 
to categorical psychiatric diagnoses and IQ scores. There is a need for 
international studies to create standardized protocols that go beyond 
diagnoses and capture dimensional endophenotypes across the full 
range of NDD-CNVs (Chawner et al., 2019, 2020). 
In conclusion, this survey within the MINDDS consortium has 
established great potential for large multi-centre studies of NDD-CNV 
carriers in Europe. The MINNDS consortium is strongly positioned to 
contribute to collaborations and exchange of knowledge and informa-
tion across Europe. The development of new pan-European studies will 
contribute to and improve knowledge of the complex relationship be-
tween NDD-CNV and clinical phenotype, resulting in improved care, 
counselling and quality of life for NDD-CNV carriers and their families 
across Europe. 
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